193 related articles for article (PubMed ID: 37501542)
1. Children's Oncology Group's 2023 blueprint for research: Diversity and health disparities.
Winestone LE; Beauchemin MP; Bona K; Kahn J; Prasad P; Robles JM; Velez MC;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30592. PubMed ID: 37501542
[TBL] [Abstract][Full Text] [Related]
2. A Tri-Institutional Approach to Address Disparities in Children's Oncology Group Clinical Trial Accrual for Adolescents and Young Adults and Underrepresented Minorities.
Mittal N; Davidson J; Martinez MF; Sanchez R; Sane N; Giordano L; Choi DK; Kent P; Dighe D; Iqbal A; Kiely C; Breen K; Quigley JG; Catchatourian R; Gitelis S; Schmidt ML
J Adolesc Young Adult Oncol; 2019 Jun; 8(3):227-235. PubMed ID: 30676208
[No Abstract] [Full Text] [Related]
3. Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.
Freyer DR; Felgenhauer J; Perentesis J;
Pediatr Blood Cancer; 2013 Jun; 60(6):1055-8. PubMed ID: 23424167
[TBL] [Abstract][Full Text] [Related]
4. Children's Oncology Group's 2023 blueprint for research: Young investigators.
Esbenshade AJ; Kahalley LS; Wistinghausen B; Cash T; Baertschiger RM; Zarnegar-Lumley S; Green A; Dhall G;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30567. PubMed ID: 37438856
[TBL] [Abstract][Full Text] [Related]
5. The Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network: A New Model for Addressing Site-Level Factors Impacting Clinical Trial Enrollment.
Roth M; Mittal N; Saha A; Freyer DR
J Adolesc Young Adult Oncol; 2020 Aug; 9(4):522-527. PubMed ID: 32077782
[No Abstract] [Full Text] [Related]
6. Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.
Faulk KE; Anderson-Mellies A; Cockburn M; Green AL
PLoS One; 2020; 15(4):e0230824. PubMed ID: 32324751
[TBL] [Abstract][Full Text] [Related]
7. Children's Oncology Group 2023 blueprint for research: Adolescent and young adult oncology.
Roth ME; Grimes AC; Reed DR; Weiss AR; Mittal N; Parsons SK; Freyer DR;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30564. PubMed ID: 37439574
[TBL] [Abstract][Full Text] [Related]
8. Loss to follow-up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group.
Puthenpura V; Ji L; Xu X; Roth ME; Freyer DR; Frazier AL; Marks AM; Pashankar FD
Cancer; 2023 May; 129(10):1547-1556. PubMed ID: 36813754
[TBL] [Abstract][Full Text] [Related]
9. Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.
Bhuta R; Shah R; Gell JJ; Poynter JN; Bagrodia A; Dicken BJ; Pashankar F; Frazier AL; Shaikh F
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30562. PubMed ID: 37449938
[TBL] [Abstract][Full Text] [Related]
10. Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group.
Esbenshade AJ; Pierson CR; Thompson AL; Reed D; Gupta A; Levy A; Kahalley LS; Harker-Murray P; Schore R; Muscal JA; Embry L; Maloney K; Horton T; Zweidler-Mckay P; Dhall G
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29193588
[TBL] [Abstract][Full Text] [Related]
11. Children's Oncology Group 2023 blueprint: Nursing discipline.
Zupanec S; Herriage T; Landier W;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30575. PubMed ID: 37470719
[TBL] [Abstract][Full Text] [Related]
12. American society of clinical oncology policy statement: disparities in cancer care.
Goss E; Lopez AM; Brown CL; Wollins DS; Brawley OW; Raghavan D
J Clin Oncol; 2009 Jun; 27(17):2881-5. PubMed ID: 19403885
[TBL] [Abstract][Full Text] [Related]
13. Children's Oncology Group's 2023 blueprint for research: Behavioral science.
Embry L; Bingen K; Conklin HM; Hardy S; Jacola LM; Marchak JG; Paltin I; Pelletier W; Devine KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30557. PubMed ID: 37430416
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute-Designated Community Oncology Research Programs.
Dickens DS; Roth ME; Pollock BH; Langevin AM
JCO Oncol Pract; 2020 Oct; 16(10):e1060-e1066. PubMed ID: 32396490
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of oncology clinical trial-embedded evaluation of social determinants of health.
Aziz-Bose R; Zheng DJ; Umaretiya PJ; Ilcisin L; Stevenson K; Koch V; Valenzuela A; Cole PD; Gennarini LM; Kahn JM; Kelly KM; Tran TH; Michon B; Welch JJG; Silverman LB; Wolfe J; Bona K
Pediatr Blood Cancer; 2022 Nov; 69(11):e29933. PubMed ID: 36069432
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Teleconsent for Adolescent and Young Adult Cancer Clinical Trials, a Report from the Children's Oncology Group.
Terao M; Mittal N; Roth M; Saha A; Super L; Reichek J
J Adolesc Young Adult Oncol; 2024 Feb; 13(1):132-137. PubMed ID: 37540127
[No Abstract] [Full Text] [Related]
17. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO; Parsons SK; Wroblewski KE; Chen L; Hong F; Smith SM; McNeer JL; Advani RH; Gascoyne RD; Constine LS; Horning S; Bartlett NL; Shah B; Connors JM; Leonard JI; Kahl BS; Kelly KM; Schwartz CL; Li H; Friedberg JW; Friedman DL; Gordon LI; Evens AM
Cancer; 2018 Jan; 124(1):136-144. PubMed ID: 28902390
[TBL] [Abstract][Full Text] [Related]
18. Children's Oncology Group's 2023 blueprint for research: Pharmacy.
Ostrenga AR; Thackray J; McLearan HH; Mulieri KM; Bisaccia E; Militano O; Dupuis LL; Bernhardt MB;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30581. PubMed ID: 37460409
[TBL] [Abstract][Full Text] [Related]
19. Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials.
Mittal N; Saha A; Avutu V; Monga V; Freyer DR; Roth M
Sci Rep; 2022 Mar; 12(1):3875. PubMed ID: 35264642
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
